Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RATIONAL HIV VACCINE

Financiado

Cerrado

Rational HIV vaccine design via mammalian cell display

This application proposes experiments to address one of the greatest challenges in HIV vaccine research: how can broadly neutralising antibodies be induced by vaccination in humans to target pathogens such as HIV, which are resist... ver más

31/01/2018

UNIVERSITY COLLEGE...

294K€

Presupuesto del proyecto: 294K€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-01-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITY COLLEGE LONDON

0.00€ | Lider

Proyectos interesantes

NGIN

Medical Technol...

Biotechnology

10M€ Cerrado

EURONEUT-41

Medical Technol...

Biotechnology

16M€ Cerrado

SHEV

Medical Technol...

Biotechnology

1M€ Cerrado

BIO2014-52683-R

Medical Technol...

Immunology

278K€ Cerrado

VIVA

Medical Technol...

Data Science

2M€ Cerrado

EIN2019-102941

Medical Technol...

Immunology

10K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 294K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This application proposes experiments to address one of the greatest challenges in HIV vaccine research: how can broadly neutralising antibodies be induced by vaccination in humans to target pathogens such as HIV, which are resistant to traditional vaccine approaches? The researcher and host labs will develop a mammalian display system using lentiviral vectors to express HIV proteins on the surface of mammalian cells and allow the in vitro evolution of different candidate vaccine immunogens in the outgoing host lab of Prof. Dennis Burton at The Scripps Research Institute. Optimisation of candidate vaccines will be achieved via random mutagenesis of the displayed immunogens followed by iterative rounds of selection for the ability to interact with novel highly potent broadly neutralizing HIV antibodies. The immunogens developed will initially be assessed for their ability to select for HIV neutralising antibodies in a novel in vitro antibody maturation system. The researcher will have access to first-rate career development advice from both hosts and via courses provided at both host institutes. The technical skills and translational skills acquired during the fellowship will be applied during the return phase in the HIV research lab of Prof. Deenan Pillay at University College London. The experimental skills acquired by the researcher will enrich the European research area during the return phase as they can be applied to other viral vaccine targets for which no effective vaccine is available e.g. influenza and hepatitis C. Thus the scientific advances made during this project have great potential significance for HIV vaccine research and the training received during the fellowship will place the researcher in an optimal position to start a research laboratory at a European Institution.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores